(Q37976539)

26 August 2017

Correlates of vaccine protection from influenza and its complications (English)

1 reference

26 August 2017

1 reference

1

Jonathan A McCullers

1 reference

26 August 2017

Victor C Huber

2

1 reference

26 August 2017

1 January 2012

1 reference

Human Vaccines & Immunotherapeutics

26 August 2017

1 reference

26 August 2017

8

1 reference

26 August 2017

1

1 reference

26 August 2017

34-44

1 reference

Mortality associated with influenza and respiratory syncytial virus in the United States

26 August 2017

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Public health. Will vaccines be available for the next influenza pandemic?

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Planning for an influenza pandemic: thinking beyond the virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Insights into the interaction between influenza virus and pneumococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Trends and epidemics of influenza and pneumonia: 1918-1951

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Pandemic 2009 influenza A in Argentina: a study of 337 patients on mechanical ventilation.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Critically Ill patients with 2009 influenza A(H1N1) in Mexico

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Lung pathology in fatal novel human influenza A (H1N1) infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

A Virus Obtained from Influenza Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Adaptation and Growth Characteristics of Influenza Virus at 25° C

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

The need for quadrivalent vaccine against seasonal influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10–11, 2007

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Changing interest among physicians toward pneumococcal vaccination throughout the twentieth century

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Review on the immunogenicity and safety of PCV-13 in infants and toddlers

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Contribution of vaccine-induced immunity toward either the HA or the NA component of influenza viruses limits secondary bacterial complications

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Antibody response to the M2 protein of influenza A virus expressed in insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

A universal influenza A vaccine based on the extracellular domain of the M2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Live attenuated versus inactivated influenza vaccine in infants and young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Antibodies to HA and NA augment uptake of influenza A viruses into cells via Fc receptor entry

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Vaccine-induced enhancement of viral infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

A multi-valent vaccine approach that elicits broad immunity within an influenza subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

A highly conserved neutralizing epitope on group 2 influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Reactions of antibodies with surface antigens of influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Changing perspective on immunization against influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Cell-mediated protection in influenza infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Glycan shielding of the influenza virus hemagglutinin contributes to immunopathology in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Efficacy of whole-cell killed bacterial vaccines in preventing pneumonia and death during the 1918 influenza pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

PB1-F2 proteins from H5N1 and 20 century pandemic influenza viruses cause immunopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Influenza enhances susceptibility to natural acquisition of and disease due to Streptococcus pneumoniae in ferrets.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Influenza virus primes mice for pneumonia from Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Cases and deaths during influenza pandemics in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Haemophilus influenzae invasive disease in the United States, 1994-1995: near disappearance of a vaccine-preventable childhood disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Changing needs of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Effectiveness of pneumococcal polysaccharide vaccine in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

A role for Streptococcus pneumoniae in virus-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Current status of group A streptococcal vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Sequence of myosin-crossreactive epitopes of streptococcal M protein

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Protective and autoimmune epitopes of streptococcal M proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Inactivated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super-infections

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Immunity to Streptococcus pneumoniae: Factors affecting production and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Impact of influenza vaccination on seasonal mortality in the US elderly population.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Mortality benefits of influenza vaccination in elderly people: an ongoing controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Immunosenescence: role and measurement in influenza vaccine response among the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Safety and immunogenicity of conventional subunit and MF59-adjuvanted influenza vaccines in human immunodeficiency virus-1-seropositive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Vaccine adjuvants revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

The immunogenicity of influenza virus vaccine in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Influenza immunization in immunosuppressed children

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Influenza immunization of adult patients with malignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Adult hospitalizations for laboratory-positive influenza during the 2005-2006 through 2007-2008 seasons in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Risk factors and outcomes among children admitted to hospital with pandemic H1N1 influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Community study of role of viral infections in exacerbations of asthma in 9-11 year old children

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009)

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Novel influenza A(H1N1) in a pediatric health care facility in New York City during the first wave of the 2009 pandemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Characteristic findings of pediatric inpatients with pandemic (H1N1) 2009 virus infection among severe and nonsevere illnesses

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Initial genetic characterization of the 1918 "Spanish" influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Correlates of protection induced by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Current status of live attenuated influenza virus vaccine in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

The antiviral activity of antibodies in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Functional constraints of influenza A virus epitopes limit escape from cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Influenza virus CTL epitopes, remarkably conserved and remarkably variable.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Pneumococcal vaccines and flu preparedness

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18214

21 January 2018

Identifiers

DOI

10.4161/HV.8.1.18214

1 reference

26 August 2017

1 reference

PubMed ID

22252001